Abstract
Objectives To measure awareness about adverse drug reaction (ADRs) reporting among doctors, pharmacists and nurses and to determine reasons of ADRs under-reporting in Pakistan.MethodsIn present study, a self-administered questionnaire was used to measure the awareness level about ADRs reporting among health care professionals (HCPs) of Pakistan. This was a cross sectional study.ResultsOut of the respondents 51 % were physicians, 29.7 % pharmacists and 19.3 % were nurses. 65.5 % of HCP population observed ADRs, out of which only 57.4 % reported these in their respective hospitals. About 77.3 % of population understood the importance of reporting ADRs while 67.3 % of population agrees that pharmacists are chief personnel for the development of system. 71.8 % of HCPs agrees that ADRs are not reported because Community pharmacy lacks legally qualified pharmacists. Only 14.3 % of HCPs population knows that there is any ADR reporting organization in Pakistan.ConclusionThe study recommends the need of such reporting system and more than half of the studied population agreed that pharmacists are required in developing such system.
Highlights
As per definition of Pharmacovigilance (PV) it is science and actions which are for the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem
The linear association of the knowledge of Adverse Drug Reactions (ADRs) reporting organization in Pakistan was not significant showing similar knowledge among three types of health care professionals (HCPs) (Table 1) indicating that there is a problem about national reporting in Pakistan across all the professionals
HCPs (84.6 %) have uncertainty whether the ADRs occurred due to drugs, unavailability of reporting forms, 71.8 % of HCPs agrees that ADRs are not reported because Community
Summary
As per definition of Pharmacovigilance (PV) it is science and actions which are for the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. The Thalidomide disaster in 1961 was the start of establishing the WHO Program for International Drug Monitoring, WHO promotes PV at the country level by working in collaboration with the Monitoring centre at Uppsala. More than 135 countries are the part of this program This program enhances patient safety for use of medicines and gives information about safe use and prevention and treatment of any Adverse Drug Reactions (ADRs) (http://www.who.int/medicines/areas/ quality_safety/safety_efficacy/pharmvigi/en/). WHO’s definition of ADRs, which has been in use for about 30 years, is “a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function” (WHO 1972). This activity is called as Shamim et al SpringerPlus (2016) 5:1778
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
